8-K ·Filed May 22, 2026

SCYX

SCYNEXIS INC
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago SEC0001178253-26-000014
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The reverse split is a mechanical adjustment to maintain Nasdaq listing compliance and does not change the company's fundamental value. Monitor for any subsequent equity offering or business development updates that could affect the post-split share price.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SCYX ▼ -5.47% at T+60d
NEUTRAL call ✗ call lost -5.47% · α vs SPY -8.19% · entry $5.45 → $5.15
Entry anchored
May 22, 03:59 PM ET
via exchange tick
T+1d
+2.92%
call +2.92% · α +2.91%
$5.61
settled 4mo ago
T+5d
-2.17%
call -2.17% · α -3.25%
$5.33
settled 4mo ago
T+20d
-29.83%
call -29.83% · α -27.88%
$3.82
settled 3mo ago
T+60d
-5.47%
call -5.47% · α -8.19%
$5.15
settled 6w ago

Price Chart

Loading chart...

Executive Summary

SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M against. The Board subsequently set the ratio at 1-for-8, effective May 29, 2026, reducing authorized shares from 150M to 18.75M. This is a routine capital structure adjustment to maintain Nasdaq listing compliance, with no fundamental business impact.

Key Facts

  • Shareholders approved reverse stock split at a ratio between 1:5 and 1:10 at a special meeting on May 19, 2026
  • Board set the specific ratio at 1-for-8 on May 19, 2026
  • Reverse stock split effective May 29, 2026; split-adjusted trading begins June 1, 2026
  • Authorized shares reduced from 150,000,000 to 18,750,000
  • No fractional shares will be issued; cash paid in lieu of fractional shares
  • Ticker symbol SCYX unchanged; new CUSIP is 811292 309

Financial Impact

No direct financial impact; authorized shares reduced from 150M to 18.75M via 1:8 reverse split. Proportional ownership unchanged except for fractional share cash-outs.

shares outstandingauthorized shares

Risk Factors

  • Post-split stock may face selling pressure from retail holders cashing out fractional shares
  • Reverse splits are often viewed negatively by the market as a sign of distress, though this is a routine compliance action
  • Reduced share count increases volatility on a per-share basis

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001178253-26-000014
Document: 0001178253-26-000014-index-headers.html0001178253-26-000014
Document: 0001178253-26-000014-index.html0001178253-26-000014
Document: 0001178253-26-000014.txt0001178253-26-000014
7 reports for SCYX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +33.49%May 11, 2026
Filters
Rows
Reports for SCYX — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
8-K
NEUTRAL ★ 2/10
$4.70 $4.45▼ −5.32%▼ −4.82%$5.12 (+8.94%)
Jun 26, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$3.87 $4.73▲ +22.22%▲ +20.83%$5.12 (+32.30%)
May 22, 2026
19w ago
8-K
NEUTRAL ★ 4/10
$5.45 $5.33▼ −2.17%▼ −3.25%$5.12 (−6.02%)
May 11, 2026
20w ago
Press Release
BEARISH ★ 7/10
$6.24 $5.26▲ +15.77%▲ +15.17%$5.12 (+17.95%)
Apr 20, 2026
23w ago
8-K
NEUTRAL ★ 3/10
$8.48 $7.89▼ −6.98%▼ −8.06%$5.12 (−39.62%)
Mar 31, 2026
26w ago
Press Release
BULLISH ★ 7/10
$7.34 $7.97▲ +8.62%▲ +4.67%$5.12 (−30.21%)
Mar 4, 2026
30w ago
Press Release
BULLISH ★ 8/10
$6.34 $7.12▲ +12.34%▲ +14.58%$5.12 (−19.24%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (38h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access